RecruitingPhase 2NCT06712823
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
Studying Congenital adrenal hyperplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Crinetics Pharmaceuticals Inc.
- Intervention
- atumelnant (CRN04894)(drug)
- Enrollment
- 150 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2025 – 2027
Study locations (9)
- Crinetics Study Site, Minneapolis, Minnesota 55454, Minneapolis, Minnesota, United States
- Crinetics Study Site, Morehead City, North Carolina, United States
- Crinetics Study Site, Córdoba, Córdoba Province, Argentina
- Crinetics Study Site, Botucatu, São Paulo, Brazil
- Crinetics Study Site, São Paulo, Brazil
- Crinetics Study Site, Munich, Bavaria, Germany
- Crinetics Study Site, Roma, Italy
- Crinetics Study Site, Birmingham, United Kingdom
- Crinetics Study Site, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06712823 on ClinicalTrials.govOther trials for Congenital adrenal hyperplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07159841A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)Crinetics Pharmaceuticals Inc.
- RECRUITINGPHASE3NCT07144163A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaCrinetics Pharmaceuticals Inc.
- RECRUITINGPHASE2NCT07187375Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years OldNeurocrine Biosciences
- RECRUITINGNANCT07473804Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)IRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNANCT07099456Fertility And Sexual Function In CAH: CALLIOPEUniversity of Roma La Sapienza
- RECRUITINGPHASE1, PHASE2NCT05669950A Trial of Lu AG13909 in Participants With Congenital Adrenal HyperplasiaH. Lundbeck A/S
- RECRUITINGNCT06754423Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase DeficiencyIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04783181A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)Adrenas Therapeutics Inc